Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
115
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

Yamin Shu1 Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of China;2 Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of China;3 Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, People’s Republic of China;4 Department of Pharmacy, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of China
,
Qilin Zhang5 Department of Pharmacy, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of China
,
Xucheng He6 Pengzhou Second People’s Hospital, Pengzhou, People’s Republic of China
&
Li Chen1 Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of China;2 Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of China;3 Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, People’s Republic of ChinaCorrespondence[email protected]
Pages 8297-8306 | Published online: 03 Nov 2021

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Yao Wang, Kaiyu Huang, Sijia Sun, Yahong Deng & Xuefeng Xie. (2022) Cost-Effectiveness Analysis of Gefitinib Alone and Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer. Risk Management and Healthcare Policy 15, pages 351-359.
Read now

Articles from other publishers (4)

Ping Du, Zhixia Zhao, Weiyue Yu, Rui Zhao, Hongchuan Liu, Pengfei Li & Lihong Liu. (2023) Pharmacokinetics, bioequivalence, and safety studies of gefitinib tablet formulations: A randomized, open-label, two-period, two-sequence crossover study in Chinese healthy volunteers. Journal of Drug Delivery Science and Technology 84, pages 104563.
Crossref
Yamin Shu, Yiling Ding, Feie Li & Qilin Zhang. (2023) Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer. International Immunopharmacology 114, pages 109589.
Crossref
Yamin Shu, Yufeng Ding, Xucheng He, Yanxin Liu, Pan Wu & Qilin Zhang. (2022) Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China. Frontiers in Pharmacology 13.
Crossref
Yamin Shu, Yufeng Ding & Qilin Zhang. (2022) Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China. Frontiers in Oncology 12.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.